WO1990013550A1 - 8α-ACYLAMINO-ERGOLINE, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL - Google Patents
8α-ACYLAMINO-ERGOLINE, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL Download PDFInfo
- Publication number
- WO1990013550A1 WO1990013550A1 PCT/DE1990/000339 DE9000339W WO9013550A1 WO 1990013550 A1 WO1990013550 A1 WO 1990013550A1 DE 9000339 W DE9000339 W DE 9000339W WO 9013550 A1 WO9013550 A1 WO 9013550A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- propyl
- ergolinyl
- alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
- C07D457/12—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to 8 ⁇ -acylaminoergolines, their production and use as medicaments and intermediates for the production of 8 ⁇ -acylaminoergolines.
- the 8 ⁇ -acylaminoergolide derivatives substituted in the 6-position with a longer-chain hydrocarbon radical according to the invention show a reduced apomorphine-antagonistic activity and increased dopamine-agomstic activity in comparison with the 6-methyl derivatives. At the same time, the metabolic stability of the compound is maintained or improved.
- the invention relates to compounds of the formula I.
- R 2 optionally substituted C 1-7 alkyl, C 2-7 alkenyl, CH 2 -OC 1-4 alkyl or CH 2 -SC 1-4 alkyl,
- R 6 C 2-6 alkyl. C 3-6 alkenyl or C 3-5 cycloalkyl-C 1-2 alkyl and
- R 8 is -CXR 3 or -SO 2 R 5 . wherein R 3 is hydrogen, optionally substituted C 1-6 alkyl,
- R 5 is CH 3 or an amino group optionally mono- or disubstituted with C 1-4 alkyl
- Alkyl is in each case to be understood as a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, hexyl, heptyl, 2,2, dimethyl-propyl, 2-methylbutyl, 3-methylbutyl, 1-ethylbutyl, isopentyl, isoheptyl, 1-methyl-ethyl-propyl.
- the alkyl radical R 2 can in particular be substituted in the 1-position with a hydroxyl, C 1-4 alkoxy or C 2-5 acyloxy group corresponding to the formula -C (OR ') R''R'', wherein R "and R""each hydrogen or alkyl radicals with max. 6 mean hydrocarbon atoms and R 'in particular
- Aliphatic carboxylic acids such as acetic acid, propionic acid, butyric acid, caproic acid and trimethyl acetic acid are suitable as acyl groups.
- R 2 or R 6 are an alkenyl radical, this preferably contains only one double bond, it being possible for the double bond in the R 6 radical not to be adjacent to the nitrogen atom.
- Suitable alkenyl radicals are, for example: vinyl, 1-propenyl, 2-propenyl, 1-methyl-2-proper ⁇ yl, 1-butenyl, methallyl, allyl.
- R 6 is a cycloalkyl-alkyl group, cyclopropylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl is meant, for example.
- the alkyl radical R 3 can be mono- or disubstituted with hydroxy,
- R 9 and R 10 form together with the nitrogen atom a saturated or unsaturated heterocycle which can be interrupted by one or two further heteroatoms, this can be replaced by oxygen, sulfur or an NH group which is optionally substituted by C 1-4 alkyl or phenyl or be interrupted by two nitrogen atoms. For example, come
- R 6 is C 2-4 alkyl, C 3-4 alkene or
- the compounds of the formula I can occur as E or Z isomers or, if a chiral center is present in the radical R 2 , as diastereomers and as mixtures thereof.
- the isomers and mixtures of isomers are also encompassed by the present invention.
- the physiologically compatible acid addition salts are derived from the known inorganic and organic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, citric acid, maleic acid, fumaric acid, tartaric acid and others.
- the compounds of the formula I and their acid addition salts have, in particular, central dopaminergic activity and can therefore be used as medicaments.
- the dopamine agonistic effect was determined using the method according to Horowski, R. and Wachtel, H. Eur. J. Pharmaz. col. 36: 373-383, 1976: One hour after ip pretreatment with test substance or vehicle, the presence of behavioral stereotypes (chewing, leakage or gnawing movements) was determined in rats for 2 min (60.-62. Min pi). Animals that chewed, leaked, or gnawed during the 2 minute interval were considered stereotyped.
- the compounds according to the invention are suitable for the treatment of dopamine deficiency states in living beings and in particular of Parkinson's disease.
- the compounds according to the invention are brought into the form of a pharmaceutical preparation which, in addition to the active ingredient for enteral or parenteral administration, has suitable pharmaceutical, organic or inorganic inert carrier materials, such as water, gelatin, gum arabic, milk sugar, starch, Contains magnesium stearate, talc, vegetable oils, polyalkylene glycols etc.
- suitable pharmaceutical, organic or inorganic inert carrier materials such as water, gelatin, gum arabic, milk sugar, starch, Contains magnesium stearate, talc, vegetable oils, polyalkylene glycols etc.
- the pharmaceutical preparations can be in solid form, for example as tablets, dragées, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. If necessary, they also contain auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure or buffers.
- the compounds according to the invention are introduced in a dose of 0.001 to 10 mg of active substance into a physiologically acceptable carrier.
- the compounds according to the invention are used in a dose of 0.00001 to 0.1 mg / kg / day, preferably 0.001 to
- the compounds of the formula I according to the invention can be prepared by methods known per se.
- R 2 and R 6 have the above meaning, acylated with an acid or its functional derivative, b) a compound of the formula II and a compound of the formula III
- acylation of the compounds of the formula I by process a) can be carried out in a conventional manner.
- the free acid R 8 OH or its reactive derivatives such as halides or anhydrides can be reacted with the amine of the formula II in the presence of a base in a suitable inert solvent at from room temperature to the boiling point of the mixed solution.
- Suitable solvents are ethers such as tetrahydrofuran, dioxane, chlorinated hydrocarbons such as dichloromethane or aprotic solvents such as DMF. If an anhydride is used for acylation, excess anhydride can also be used as the solvent.
- the formylation is advantageously carried out using a mixed anhydride of acetic acid and formic acid.
- Suitable bases are, for example, methylamine, Hunig bases or 2,6-lutidine or the acylation is carried out in pyridine as solvent.
- the urea and thiourea derivatives can be prepared, for example, via reactive imidazolides which are obtained from N, N-carbonyldiimidazole or N, N-thiocarbonyldiimidazole and primary and secondary amines R 9 R 10 NH. Also by reaction with carbamoyl chlorides R 9 R 10 NCO-Cl
- amines to isocyanates or isothiocyanates according to process b) can be carried out by the method described in EP-82 808, for example in an inert solvent such as hydrocarbons, chlorinated hydrocarbons, ethers or esters, for example in hexane, toluene, dichloromethane, diethyl ether, Ethyl acetate and others the reaction is carried out at room temperature or elevated temperature.
- an inert solvent such as hydrocarbons, chlorinated hydrocarbons, ethers or esters
- the substituents can be introduced in the 6 or 2 position before or after the acylation in the 8 position.
- the 6-position substitution according to method c) can be carried out, for example, according to A. Cerny et al. Coll. Czech. Chem. Comm. 49, 2828 (1984) or according to the process described in EP-21 206, by reacting the 6H compound of the formula IV with the corresponding R 6 halides (bromides, chlorides, iodides).
- the reaction is expediently carried out in an inert solvent such as dimethyl sulfoxide, dimethylformamide, acetonitrile or nitromethane in the presence of bases such as alkali metal hydroxides or carbonates.
- the introduction of the substituent R 2 can, for example, according to the
- Substituent R 2 are introduced.
- the nucleophilic exchange takes place, if appropriate, after quaternization of the Mannich base in a polar, protic or aprotic solvent such as alcohols, ethers or chlorinated hydrocarbons at room temperature or elevated temperature, alcoholates or thiolates being able to be used as nucleophilic anions, which, if desired, can subsequently be converted into the CH -OH group can be.
- a polar, protic or aprotic solvent such as alcohols, ethers or chlorinated hydrocarbons at room temperature or elevated temperature, alcoholates or thiolates being able to be used as nucleophilic anions, which, if desired, can subsequently be converted into the CH -OH group can be.
- the Ouartar salt of formula V can be reduced in polar solvents such as alcohols with sodium borohydride.
- the oxidation to a 2-CHO compound can be carried out analogously to that in RA Jones et al. Synthetic Communications 16, 1799 (1986) described methods with manganese dioxide or tert. Butyl hypochlorite in inert solvents at room temperature.
- the conversion of the 2-formyl compounds to compounds of the formula I in which R 2 denotes an alkenyl radical can be carried out in one
- Wittig reactions take place, such as, for example, with alkyl triphenylphosphonium halo in polar solvents such as cyclic and acyclic ethers, chlorinated hydrocarbons, dimethylformamide or dimethyl sulfoxide at temperatures from -50 ° C. to the boiling point of the reaction mixture, strong bases such as alkali metal alcoholates being used to produce the ylene , Lithiumorganyl, etc. are added.
- Substituents R 2 which are hydroxylated in the 1-position can be prepared, for example, by reaction of the aldehydes and ketones with Grignard compounds or lithium organyls.
- the Grignardation can be carried out with the usual Grignard reagents such as alkyl magnesium halogens in an aprotic solvent such as cyclic and acyclic ethers at low temperatures (-70 ° C to 0 ° C).
- the reaction with alkyl lithium takes place under analogous conditions.
- the acetylation of a hydroxyl group can be carried out by the customary methods, for example by reaction with acid anhydrides or acid chlorides. If the substituent R 2 contains a hydroxyl group, this can be reduced to the corresponding 2-alkyl derivative, for example by reaction with Na BH 4 in glacial acetic acid, or oxidized with manganese dioxide to the ketone or dehydrated with the introduction of a double bond.
- Substituent R 2 is a double bond, this can be catalytically reduced, for example.
- the introduction of the substituent R 2 -C (OH) R “" R “” can be carried out as described above by reacting the ketone with Grignard compounds or lithium organylene.
- reaction conditions mentioned under process variant b) are suitable for the reaction.
- Alcohols, primary and secondary amines and mercaptans of the formula HR 3 can be used as nucleophiles, where R 3
- SC 1-6 alkyl -O- (CH 2 ) n -N (CH 3 ) 2 or NR 9 R 10 .
- the optionally subsequent stereoselective hydrogenation of the 2,3-double bond can be carried out, for example, by the processes described in EP-A-286 575 in the presence of an acid with organylsilanes or with hydrogen / noble metal catalysts.
- the conversion of the amides and urea derivatives into the thioamides and thiourea derivatives can be carried out, for example, by the process described in EP-A-217 730 by reaction with phosphorus oxychloride and a thiolating agent or with Lawesson's reagent according to Fieser and Fieser Reagents for Org. Synth. IX, 49 take place.
- the compounds of formula I are isolated either as free bases or in the form of their physiologically tolerable acid addition salts. To form salts, a compound of the formula I is dissolved, for example, in a little methanol or methylene chloride and a concentrated solution of the desired acid is added.
- the isomer mixtures can be separated into the diastereomers or E / Z isomers by conventional methods such as, for example, crystallization, chromatography or salt formation.
- the invention also includes compounds of the formula II
- 6-n-Propyl-2-v ⁇ nyl-8 ⁇ -ergol ⁇ ncarbonsauremethylester (10 mmol) in 50 ml of tetrahydrofuran at - 30 ° C, stirred for 30 minutes at this temperature and then acidified with 10% hydrochloric acid. After warming to room temperature, saturated bicaxbonate solution is added, the mixture is shaken with dichloromethane and the organic phase is separated off, dried and evaporated. The residue is chromatographed on silica gel with dichloromethane / methanol. Yield of 6-n-propyl-2-vinyl-8 ⁇ -ergoline carboxylic acid methyl ester 2.0 g (60% of theory).
- the 8 ⁇ -ester is converted into the corresponding hydrazine with hydrazine hydrate / hydrazine hydrochloride in propanol, nitrosated with sodium nitrite in hydrochloric acid solution to give 8 ⁇ -ergoline carboxylic acid reagent and the azide is rearranged at 80 ° C. After cooling, working up as described above and the residue crystallized, yield 1.33 g (45% of theory) 6-n-propyl-2-v ⁇ nyl-8 ⁇ -ergol ⁇ nylamine.
- 2,3 ⁇ -dihydro-8 ⁇ -ergol ⁇ nylamines can be prepared from the corresponding ergolinyl ureas.
- N- (9,10-didehydro-2,3-dihydro-2-methyl-6-n-propyl-8 ⁇ -ergol ⁇ nyl) acetoxyacetamide is obtained by oxidation with tert-butyl hypochlorite N- (9.10 -Didehydro-2-methyl-6-n-propyl-8 ⁇ -ergolinyl) -acetoxyacetamide. Yield 63%.
- N- (9,10-didehydro-2,3 ⁇ -dihydro-2-methyl-6-npropyl-8 ⁇ -ergolinyl) -2-methyl-propionamide is obtained by oxidation with tert-butyl hypochlorite N- (9 , 10-Didehydro-2-methyl-6-n-propyl-8 ⁇ -ergol ⁇ nyl) -2-methyl-propionamide, yield 72%.
- N- (2-methyl-6-n-propyl-8 ⁇ -ergolinyl) -2-methyl-thiopropionic acid amide 353 mg of N- (methyl-6-n-propyl-8 ⁇ -ergolinyl) -2-methylpropionamide (1 mmol) are suspended in 20 ml of toluene, 404 mg of 2,4-bis- (4-dimethoxyphenyl-1, 2,3,4-dithiadiphosphetane-2,4-disulfide (2 mmol) (Lawesson's reagent) and heated for 3 hours at 100 ° C.
- Example 18 If sodium methane thiolate is used as the nucleophile analogously to Example 16, the title compound is obtained in dichloromethane in a yield of 37%.
- Example 18 If sodium methane thiolate is used as the nucleophile analogously to Example 16, the title compound is obtained in dichloromethane in a yield of 37%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90906872A EP0427827B1 (de) | 1989-05-12 | 1990-05-10 | 8-alpha-ACYLAMINO-ERGOLINE, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL |
DE59010633T DE59010633D1 (de) | 1989-05-12 | 1990-05-10 | 8-alpha-ACYLAMINO-ERGOLINE, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP3915950.7 | 1989-05-12 | ||
DE3915950A DE3915950A1 (de) | 1989-05-12 | 1989-05-12 | 8(alpha)-acylamino-ergoline, ihre herstellung und verwendung als arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990013550A1 true WO1990013550A1 (de) | 1990-11-15 |
Family
ID=6380759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1990/000339 WO1990013550A1 (de) | 1989-05-12 | 1990-05-10 | 8α-ACYLAMINO-ERGOLINE, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL |
Country Status (14)
Country | Link |
---|---|
US (2) | US5212178A (de) |
EP (1) | EP0427827B1 (de) |
JP (1) | JPH04500681A (de) |
AT (1) | ATE147742T1 (de) |
CA (1) | CA2028832A1 (de) |
CZ (2) | CZ278981B6 (de) |
DD (1) | DD294259A5 (de) |
DE (2) | DE3915950A1 (de) |
DK (1) | DK0427827T3 (de) |
ES (1) | ES2098263T3 (de) |
HU (1) | HU212814B (de) |
PT (1) | PT94011B (de) |
SK (2) | SK277996B6 (de) |
WO (1) | WO1990013550A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018332A (en) * | 1997-11-21 | 2000-01-25 | Ark Interface Ii, Inc. | Overscan user interface |
US8113807B2 (en) * | 2007-08-24 | 2012-02-14 | Timothy Wilkinson | Methods and apparatus for fabricating structures |
CA2859173A1 (en) * | 2011-12-19 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
US9657020B2 (en) | 2015-01-20 | 2017-05-23 | Xoc Pharmaceuticals, Inc. | Ergoline compounds and uses thereof |
BR112017015510A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo |
BR112019025420A2 (pt) | 2017-06-01 | 2020-06-16 | Xoc Pharmaceuticals, Inc. | Compostos policíclicos e usos destes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH615929A5 (en) * | 1975-06-02 | 1980-02-29 | Sandoz Ag | Process for the preparation of novel ergoline compounds |
DE3500251A1 (de) * | 1984-01-12 | 1985-07-18 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue 8(alpha)-acylaminoergoline |
EP0160842A2 (de) * | 1984-04-09 | 1985-11-13 | Schering Aktiengesellschaft | 2-substituierte Ergolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP0250357A1 (de) * | 1986-06-16 | 1987-12-23 | Schering Aktiengesellschaft | 1- und/oder 2-substituierte Ergolinderivate |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2864822A (en) * | 1956-10-22 | 1958-12-16 | Lilly Co Eli | 9-amino-7-methyl-belta10-ergolene and derivatives thereof |
WO1982000463A1 (en) * | 1980-07-25 | 1982-02-18 | Ag Sandoz | Ergoline derivatives,method for their preparation,pharmaceutical compositions containing them and their therapeutic application |
DE3135305C2 (de) * | 1981-09-03 | 1983-07-21 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 8-Ergolinyl-harnstoffen |
DE3151912A1 (de) * | 1981-12-23 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel |
NL8400333A (nl) * | 1983-02-16 | 1984-09-17 | Sandoz Ag | Moederkoornalkaloiden, hun bereiding en hun toepassing. |
DE3309493A1 (de) * | 1983-03-14 | 1984-09-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue ergolin-derivate, verfahren zu ihrer herstellung sowie verwendung als arzneimittel |
DE3544365A1 (de) * | 1984-12-24 | 1986-07-03 | Sandoz-Patent-GmbH, 7850 Lörrach | 8(alpha)-acylaminoergoline |
NL8503426A (nl) * | 1984-12-24 | 1986-07-16 | Sandoz Ag | 8alfa-acylamino-ergolinen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten. |
DE3528584A1 (de) * | 1985-08-06 | 1987-02-19 | Schering Ag | Neue 1-alkyl-ergolin-thioharnstoffderivate |
DE3700825A1 (de) * | 1986-01-24 | 1987-07-30 | Sandoz Ag | 8(alpha)-acylaminoergoline, ihre herstellung und verwendung |
NL8700046A (nl) * | 1986-01-24 | 1987-08-17 | Sandoz Ag | 8 alfa-acylaminoergolinen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten. |
DE3708028A1 (de) * | 1987-03-10 | 1988-09-22 | Schering Ag | Verfahren zur herstellung von 2,3ss-dihydroergolinen, 2-substituierte 2,3ss-dihydroergoline und ihre verwendung als arzneimittel |
-
1989
- 1989-05-12 DE DE3915950A patent/DE3915950A1/de not_active Ceased
-
1990
- 1990-05-10 WO PCT/DE1990/000339 patent/WO1990013550A1/de active IP Right Grant
- 1990-05-10 DK DK90906872.8T patent/DK0427827T3/da active
- 1990-05-10 EP EP90906872A patent/EP0427827B1/de not_active Expired - Lifetime
- 1990-05-10 CA CA002028832A patent/CA2028832A1/en not_active Abandoned
- 1990-05-10 JP JP2506904A patent/JPH04500681A/ja active Pending
- 1990-05-10 AT AT90906872T patent/ATE147742T1/de not_active IP Right Cessation
- 1990-05-10 ES ES90906872T patent/ES2098263T3/es not_active Expired - Lifetime
- 1990-05-10 DE DE59010633T patent/DE59010633D1/de not_active Expired - Lifetime
- 1990-05-10 HU HU904426A patent/HU212814B/hu not_active IP Right Cessation
- 1990-05-11 SK SK2604-91A patent/SK277996B6/sk unknown
- 1990-05-11 DD DD90340575A patent/DD294259A5/de not_active IP Right Cessation
- 1990-05-11 CZ CS902331A patent/CZ278981B6/cs unknown
- 1990-05-11 CZ CS912604A patent/CZ279080B6/cs unknown
- 1990-05-11 SK SK2331-90A patent/SK233190A3/sk unknown
- 1990-05-11 PT PT94011A patent/PT94011B/pt not_active IP Right Cessation
- 1990-05-14 US US07/522,751 patent/US5212178A/en not_active Expired - Fee Related
-
1994
- 1994-12-27 US US08/364,015 patent/US5547958A/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH615929A5 (en) * | 1975-06-02 | 1980-02-29 | Sandoz Ag | Process for the preparation of novel ergoline compounds |
DE3500251A1 (de) * | 1984-01-12 | 1985-07-18 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue 8(alpha)-acylaminoergoline |
EP0160842A2 (de) * | 1984-04-09 | 1985-11-13 | Schering Aktiengesellschaft | 2-substituierte Ergolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP0250357A1 (de) * | 1986-06-16 | 1987-12-23 | Schering Aktiengesellschaft | 1- und/oder 2-substituierte Ergolinderivate |
Also Published As
Publication number | Publication date |
---|---|
EP0427827A1 (de) | 1991-05-22 |
CZ278981B6 (en) | 1994-11-16 |
PT94011A (pt) | 1991-01-08 |
HU212814B (hu) | 1998-08-28 |
ATE147742T1 (de) | 1997-02-15 |
HUT56363A (en) | 1991-08-28 |
SK260491A3 (en) | 1995-09-13 |
PT94011B (pt) | 1996-12-31 |
EP0427827B1 (de) | 1997-01-15 |
DE3915950A1 (de) | 1990-11-15 |
JPH04500681A (ja) | 1992-02-06 |
ES2098263T3 (es) | 1997-05-01 |
US5547958A (en) | 1996-08-20 |
DK0427827T3 (da) | 1997-07-07 |
CZ279080B6 (en) | 1994-12-15 |
SK277997B6 (en) | 1995-09-13 |
DD294259A5 (de) | 1991-09-26 |
SK233190A3 (en) | 1995-09-13 |
CA2028832A1 (en) | 1990-11-13 |
DE59010633D1 (de) | 1997-03-06 |
CZ233190A3 (en) | 1994-02-16 |
HU904426D0 (en) | 1991-07-29 |
US5212178A (en) | 1993-05-18 |
SK277996B6 (en) | 1995-09-13 |
CZ260491A3 (en) | 1993-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0351352B1 (de) | 2-Substituierte Ergoline, ihre Herstellung und Verwendung | |
EP0427827B1 (de) | 8-alpha-ACYLAMINO-ERGOLINE, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL | |
CH670644A5 (de) | ||
DE69632919T2 (de) | Verfahren zur herstellung von 2-chlor-5-chloromethyl-thiazol | |
DE3413657A1 (de) | Neue ergoline | |
EP0008652A1 (de) | Neue Zwischenprodukte und deren Verwendung zur Herstellung von neuen Oxadiazolopyrimidinderivaten | |
WO1993001185A1 (de) | 2,14-disubstituierte ergoline, deren herstellung und verwendung in arzneimitteln | |
EP0217734B1 (de) | 12- und 13-Brom-Ergolinderivate | |
DE2601473A1 (de) | 2,3-dihydroergoline und verfahren zu ihrer herstellung | |
EP0418990B1 (de) | 13-Brom und 13, 14-Dibrom-Ergoline, ihre Herstellung und Verwendung in Arzneimitteln | |
DE1246722B (de) | Verfahren zur Herstellung von Harnstoffderivaten | |
WO1990012796A1 (de) | 8β-SUBSTITUIERTE ERGOLINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG | |
EP0463139B1 (de) | 2,13-disubstituierte ergoline, deren herstellung und verwendung in arzneimitteln | |
EP0213062B1 (de) | 1-Alkyl-ergolinyl-thioharnstoffderivate | |
EP1631552B1 (de) | Verfahren zur synthese heterocyclischer verbindungen aus thioharnstoffderivaten | |
EP0217735A2 (de) | Neue 2-substituierte Ergolinderivate | |
DE19712411A1 (de) | Verfahren zur Herstellung von 1,3-disubstituierten 2-Nitroguanidinen | |
DE3824659A1 (de) | 2-, 12- oder 13-substituierte 3-(8'(alpha)-ergolinyl)-1,1-diethylharnstoffe, ihre herstellung und verwendung in arzneimitteln | |
EP0136662B1 (de) | 2,6-Dioxa-Bicyclo-[2,2,2]-octan-7-yl-acetaldehyde | |
DE3831465A1 (de) | Basische spaltungsprodukte von elaiophylin und elaiophylinderivaten und verwendung derselben | |
AT336602B (de) | Verfahren zur herstellung eines optisch aktiven thiolactons | |
AT269368B (de) | Verfahren zur Herstellung neuer heterocyclischer Verbindungen | |
DE3938701A1 (de) | Neue agroclavin- und elymoclavin-derivate, verfahren zu deren herstellung und deren verwendung in arzneimitteln | |
DE3941967A1 (de) | Neue phosphor- und phosphorigsaeureamide von ergolinen | |
DE4020341A1 (de) | Verfahren zur herstellung von 2-hydroxymethyl-ergolinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1990906872 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2028832 Country of ref document: CA |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA HU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1990906872 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990906872 Country of ref document: EP |